Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2644 studies found for:    Mexico
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
2 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
3 Recruiting A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Condition: Follicular Lymphoma
Interventions: Biological: PF-05280586;   Biological: MabThera®
4 Recruiting Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Condition: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions: Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
5 Recruiting Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Conditions: Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions: Drug: Canagliflozin;   Drug: Placebo
6 Completed Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
Condition: Influenza
Interventions: Drug: favipiravir;   Drug: placebo
7 Active, not recruiting The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo
8 Recruiting The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo
9 Recruiting Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
Condition: Severe IgE-mediated Asthma
Interventions: Drug: Omalizumab;   Drug: Budesonide;   Drug: Formoterol
10 Active, not recruiting Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: Linagliptin
11 Recruiting A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Conditions: Heart Failure;   Coronary Artery Disease
Interventions: Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
12 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab;   Drug: Placebo
13 Terminated
Has Results
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
Conditions: Type 2 Diabetes;   Cardiovascular Disease
Interventions: Drug: TAK-875;   Drug: TAK-875 Placebo
14 Recruiting GLORIA-AF Registry Program - Second and Third Phases
Conditions: Stroke;   Atrial Fibrillation
Intervention:
15 Completed A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: Etanercept;   Drug: Tocilizumab
16 Completed Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
Conditions: ACS;   Acute Coronary Syndrome;   Myocardial Infarction;   Unstable Angina;   Coronary Artery Disease
Intervention:
17 Completed Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010);   Drug: placebo
18 Active, not recruiting Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities
Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat;   Drug: Allopurinol
19 Completed A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Aleglitazar;   Drug: Placebo
20 Completed
Has Results
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
Conditions: Diabetes Mellitus, Type 2;   Acute Coronary Syndrome
Interventions: Drug: Alogliptin;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years